Jennifer Levin Carter, MD, MPH, MBA is a healthcare executive, Board member and entrepreneur with a successful track record of developing innovative strategies and solutions at the intersection of and healthcare IT and services, digital health and machine learning, precision medicine, genomics and its application to healthcare delivery and life sciences including novel clinical trial delivery and drug development. She was most recently, VP and of Head of Precision Health at Integral Health, A Flagship Pioneering company. In 2018, She Founded TrialzOWN, Inc. a novel clinical trials company in stealth, and was CEO until it’s prelaunch acquisition by Integral Health in March, 2019. Prior to TrialzOWN, Dr. Carter was the Founder and President of N-of-One®, Inc. She served at CEO from 2008-2012, and Chief Medical Officer from 2012 until its acquisition by Qiagen (Market Cap $8B) in 2019. At N-of-One, Dr. Carter led the creation of award winning solutions that delivered novel treatment strategies to hundreds of thousands of patients with cancer globally. Prior to founding and leading N-of-One®, Dr. Carter spent nine years working as an Investment Consultant with Levin Capital Strategies ($13B under management) and with other groups specializing in biotechnology and life sciences investments evaluating existing and emerging markets, new medical technologies, and early-stage companies. After obtaining her MD, Jennifer practiced internal medicine at Mount Auburn Hospital in Cambridge, MA. Dr. Carter graduated Phi Beta Kappa, Summa Cum Laude with distinction with a BS in Molecular Biophysics and Biochemistry from Yale University, an MD from Harvard Medical School, an MPH from Harvard School of Public Health and an MBA from the Sloan School at Massachusetts Institute of Technology.